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Double-stranded-RNA (dsRNA)-dependent protein kinase PKR is induced by interferon and activated upon
autophosphorylation. We previously identified four autophosphorylated amino acids and elucidated their
participation in PKR activation. Three of these sites are in the central region of the protein, and one is in the
kinase domain. Here we describe the identification of four additional autophosphorylated amino acids in the
spacer region that separates the two dsRNA-binding motifs in the RNA-binding domain. Eight amino acids,
including these autophosphorylation sites, are duplicated in hepatitis C virus (HCV) envelope protein E2. This
region of E2 is required for its inhibition of PKR although the mechanism of inhibition is not known.
Replacement of all four of these residues in PKR with alanines did not dramatically affect kinase activity in
vitro or in yeast Saccharomyces cerevisiae. However, when coupled with mutations of serine 242 and threonines
255 and 258 in the central region, these mutations increased PKR protein expression in mammalian cells,
consistent with diminished kinase activity. A synthetic peptide corresponding to this region of PKR was
phosphorylated in vitro by PKR, but phosphorylation was strongly inhibited after PKR was preincubated with
HCV E2. Another synthetic peptide, corresponding to the central region of PKR and containing serine 242, was
also phosphorylated by active PKR, but E2 did not inhibit this peptide as efficiently. Neither of the PKR
peptides was able to disrupt the HCV E2-PKR interaction. Taken together, these results show that PKR is
autophosphorylated on serine 83 and threonines 88, 89, and 90, that this autophosphorylation may enhance
kinase activation, and that the inhibition of PKR by HCV E2 is not solely due to duplication of and competition
with these autophosphorylation sites.
Hepatitis C virus (HCV) is an emerging pathogen of increas-
ing medical significance. As many as 2% of the world popula-
tion may now be infected with HCV, and possibly 90% of these
individuals will become chronically infected (14). The only
approved therapies for HCV are alpha interferon (IFN-a)
monotherapy or combination therapy with ribavirin. IFN is
only effective in about 10% of patients, but in these patients
a sustained response is accompanied by clearance of viral
RNA. Genotypic variants display different rates of response to
IFN-a, and these genotypes are characterized by mutations
that may be responsible for IFN-a resistance or sensitivity (12).
Two HCV proteins that have been implicated in IFN resis-
tance through inhibition of the IFN-a-induced, double-strand-
ed-RNA (dsRNA)-activated protein kinase (PKR) are NS5A
and E2 (19, 52). The nonstructural protein, NS5A, contains
mutations in a region known as the IFN-a-sensitivity-deter-
mining region in Japanese isolates; these mutations result in a
lack of PKR binding to NS5A and thus IFN-a sensitivity (for a
review, see reference 50). E2 contains a region of identity with
PKR and its substrate, eIF2a, termed the PKR-eIF2a phos-
phorylation site homology domain or PePHD; although the
exact mechanism is unknown, this region is required for PKR
inhibition (52).
PKR is a serine/threonine kinase found in cells in a latent
state. It plays a part in cellular antiviral defense as well as in
apoptosis, signal transduction, and transformation (reviewed
in references 10, 24, 38, and 56). PKR is activated by auto-
phosphorylation upon binding to its regulator, dsRNA, and
similar molecules (24, 38). Activation apparently occurs by an
intermolecular autophosphorylation reaction (26, 55), permit-
ting the enzyme to phosphorylate its substrates. Best known of
these is translational initiation factor eIF2, which is phosphor-
ylated on serine 51 of its a subunit (15, 39). Phosphorylation of
eIF2a mediates a number of cellular processes, most notably
the shutoff of protein synthesis (reviewed in references 10, 24,
and 56). PKR also phosphorylates several cellular and viral
proteins, including the human immunodeficiency virus trans-
activator protein, Tat (5, 34), and 90-kDa proteins from rabbit
reticulocytes (40) and human cells (8, 53; L. Parker, I. Fierro-
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Monti, and M. B. Mathews, unpublished data). PKR mediates
the phosphorylation of IkB, the inhibitor of NF-kB (27, 32, 36),
in response to dsRNA although the role of PKR in this path-
way is unclear (4). Phosphorylation of IkB enables NF-kB to
translocate to the nucleus, and both NIK and IKK are com-
ponents in this pathway (reviewed in reference 2). Transgenic
mice devoid of functional PKR are unresponsive to activators
of NF-kB, further supporting the role of PKR in signal trans-
duction pathways (28). The roles of the other phosphorylation
events are as yet unknown.
In addition to PKR, three other kinases can regulate protein
synthesis through phosphorylation of eIF2 (7, 22, 44). In re-
ticulocytes, the heme-regulated inhibitor, HRI, controls pro-
tein synthesis levels in response to the availability of heme (7).
The yeast Saccharomyces cerevisiae regulates amino acid bio-
synthesis through translational derepression of transcriptional
activator GCN4 via GCN2 kinase, and a homologue of the
yeast enzyme has recently been isolated in Drosophila melano-
gaster (22). Recently described eIF2 kinase PERK or PEK is
responsible for reduced protein synthesis during endoplasmic
reticulum stress (44).
PKR has homology with these kinases in its catalytic domain,
which occupies the C-terminal half of the protein. The N-
terminal one-third of PKR appears to function as its regulatory
domain and has homology with other dsRNA-binding proteins
(6, 21, 25, 49). The RNA-binding domain (RBD) of PKR
consists of two repeats of a 65- to 68-amino-acid-long motif,
the dsRNA-binding motif (dsRBM); these repeats are rich in
basic amino acids (17). The repeats, dsRBM-1 and dsRBM-2
(amino acids 11 to 77 and 101 to 167, respectively), are sepa-
rated by a short unstructured spacer (6, 16, 20, 21, 23, 35, 37,
43, 49). The spacer region is important for RNA binding, as a
mutant with a large deletion within this region fails to bind
RNA efficiently (21), possibly because of structural constraints
between dsRBM-1 and dsRBM-2. Separating the RBD from
the kinase domain of PKR is the central region (amino acids
233 to 268), which is also rich in basic amino acids but which is
not homologous to the dsRBMs.
Four sites of autophosphorylation in PKR have been de-
scribed (42, 51), out of a total of 14 sites that may be phos-
phorylated in vivo in yeast (58). Three of these sites are located
in the central region and participate in activation of the kinase.
These sites were identified through peptide mapping and se-
quencing of PKR phosphorylated during activation by dsRNA
in vitro. The fourth and possibly fifth sites of autophosphory-
lation were identified through mass spectrometry and genetic
analysis (42). These sites are located in the activation loop
within the kinase domain and play a role in kinase activation.
Here we describe the identification of four prominent auto-
phosphorylation sites that are located in the spacer region
between the two dsRBMs in the RBD. Mutagenesis of these
four autophosphorylation sites did not affect enzyme activation
in yeast or in vitro or the binding of dsRNA but led to de-
creased PKR expression in mammalian cells when combined
with mutations of other autophosphorylation sites in the cen-
tral region of PKR. These results suggest that phosphorylation
of serine 83 and threonines 88, 89, and 90 contribute to full
activation of the kinase. Eight amino acids in the sequence
containing these phosphorylation sites are identical to residues
in the HCV E2 protein. HCV E2 inhibited the phosphorylation
of PKR peptides, particularly that of the peptide that corre-
sponds to the homologous region in the spacer. The PKR
peptides did not effectively compete with HCV E2 for binding
to PKR, however, suggesting that the inhibition of PKR is not
due to simple competition at these autophosphorylation sites.
MATERIALS AND METHODS
Generation of radiolabeled peptides. PKR, purified to the mono-S stage from
IFN-a-treated 293 cells (26), was activated in vitro in the presence of reovirus
dsRNA (provided by A. Shatkin) and [g-32P]ATP under conditions described
previously (51). Radiolabeled PKR was immunoprecipitated with a polyclonal
antibody (21) and was eluted from protein A-Sepharose beads with formic acid,
digested with cyanogen bromide (CNBr) as described previously (51), and ly-
ophilized. The CNBr digestion products were separated by high-performance
liquid chromatography (HPLC) (51), fractions were collected and counted by
Cerenkov radiation, and the radioactive peaks were pooled. Radiolabeled pep-
tides were resolved in Tris-Tricine gels (47); the gels were fixed, dried, and
exposed to film for autoradiography.
Secondary peptidase digestion. Secondary digestion of radiolabeled PKR pep-
tides was performed with the following enzymes: endoproteinases Lys-C, Asp-N,
and Arg-C (sequencing grade; Boehringer Mannheim); trypsin (tolylsulfonyl
phenylalanyl chlomethyl ketone treated; Sigma); chymotrypsin (TLCK [Na-p-
tosyl-L-lysine chloromethyl ketone] treated; Sigma); and Staphylococcus aureus
V8 (Sigma). Digestion with Arg-C was conducted in accordance with the man-
ufacturer’s specifications, and digestion with Lys-C, Asp-N, trypsin, and chymo-
trypsin was performed as described previously for Lys-C (51).
Radioactive sequence analysis. Secondary digests were lyophilized, resus-
pended in 60% acetonitrile, and coupled to arylamine-derivatized polyvinylidene
difluoride (PVDF) membranes (Sequalon AA; Millipore) with carbodiimide.
PVDF-bound peptides were subjected to repetitive Edman degradation reac-
tions on a protein sequencer (Applied Biosystems; 473A) (45), and radioactivity
was monitored as described above.
Kinase assays. For peptide phosphorylation kinetics and phosphoamino acid
analysis, mono S-purified PKR (26) was added to a kinase reaction mixture (51)
and the mixture was incubated with dsRNA and [g-32P]ATP at 30°C for 20 min.
For preincubation assays, peptides were incubated with PKR before addition of
dsRNA and ATP. Peptide P1 consists of amino acids 77 to 113 of PKR:
H-KEKKAVSPLLLTTTNSSEGLSMGNYIGLINRIAQKKR-OH. Peptide P2
consists of amino acids 230 to 254 of PKR: H-NGLRNNQRKAKRSLAPRFD
LPDMKE-OH. Incubations were conducted at 30°C for 20 min unless otherwise
specified, and peptides were analyzed in sodium dodecyl sulfate (SDS)–20%
polyacrylamide gels, which were fixed, dried, and exposed to Kodak XAR-5 film
for autoradiography. Phosphoamino acid analysis was performed as described
previously (51). For assays with PKR from yeast, extracts were prepared from
H1817 cultures induced with synthetic minimal medium containing 10% galac-
tose and 2% raffinose as described previously (51) and protein concentrations
were determined using a Coomassie blue dye-binding assay (Bio-Rad). Yeast
extracts (50 mg of protein) were immunoprecipitated with a polyclonal anti-PKR
antibody (21) and protein A-Sepharose. The immunoprecipitates were washed
and then incubated as described above. To assay eIF2 phosphorylation, eIF2 was
added after the initial incubation (as described in reference 33) and incubation
resumed for another 20 min at 30°C.
Mutagenesis. Sites of autophosphorylation were mutated by the oligonucleo-
tide-directed site-specific mutagenesis procedure (1, 60). Serine and threonine
residues were changed to alanine to generate RBD mutant S83A/T88A/T89A/
T90A, triple mutant S242A/T255A/T258A (51), and combination mutant Tri-
RBD, which has all seven sites changed to alanine. Mutations were made in
pUC19D (21), which contains the full-length PKR cDNA.
PKR expression in S. cerevisiae. PKR mutants were subcloned into pEMBLyex4
as described previously (43). Plasmids bearing the autophosphorylation site mu-
tations were introduced into yeast strains H1816 and H1817 (13), which both
have GCN2 deleted; in addition, H1817 has mutant eIF2a (S51A).
Phosphatase treatment. Total cellular protein extracts (15 mg) from trans-
formed H1817 cells were treated with lambda phosphatase in accordance with
the manufacturer’s specifications (New England Biolabs) or were incubated in
phosphatase buffer alone and were resolved in SDS–10% polyacrylamide gels.
The proteins were then transferred to nitrocellulose for Western blotting. The
membrane was incubated in 5% nonfat milk in Tris-buffered saline–Tween 20
(51) and probed with a monoclonal anti-PKR antibody (30), and the proteins
were visualized by chemiluminescence (ECL; Amersham).
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PKR expression in mammalian cells. PKR mutants were subcloned into
pcDNA3 (Invitrogen). Monolayers of COS1 cells in 10-cm-diameter plates were
transfected in duplicate with plasmids (15 mg) bearing the autophosphorylation
site mutations, as well as a transfection efficiency control, by the calcium phos-
phate method (46). Cytoplasmic extracts were prepared at 48 h posttransfection,
and total protein concentration was measured by a Coomassie blue assay (Bio-
Rad). To assess the amount of PKR protein that was present in each sample, 100
mg of total protein was examined by Western blotting as described above. The
upper half of the blot was probed with the PKR monoclonal antibody (30), and
the lower half of the blot was probed with an actin polyclonal antibody (Santa
Cruz Biotechnology).
HCV E2 peptide phosphorylation inhibition assay. PKR from yeast H1817
strain was autophosphorylated as in the kinase assay described above. Glutathi-
one-coated Sepharose beads were used to purify bacterially expressed gluta-
thione S-transferase (GST) protein or GST fused to the HCV E2 protein as
described previously (52). The protein was eluted with glutathione, and 0.5 mg
was incubated with the immunoprecipitated PKR initially for 20 min at 30°C.
Poly(I:C) and [g-32P]ATP were added, and the incubation continued for another
10 min. Then peptide (3 mg) P1 or P2 was added, and incubation continued
for an additional 10 min at 30°C. The reactions were analyzed as described
above.
HCV E2 binding and peptide competition assay. Histidine-tagged PKR was
bound to nickel-Sepharose beads as described previously (52). HCV E2 was
synthesized in vitro with the T7 TNT-quick (Promega) coupled transcription-
translation system in the presence of [35S]methionine (New England Nuclear,
DuPont). Increasing amounts of synthetic peptide P1 or P2 were added to the
PKR-bound beads in 0.25 M Tris (pH 8.0)–0.1% NP-40–10 mM imidazole.
Radiolabeled E2 (5 ml of the in vitro translation reaction mixture) was then
added, and the mixture was incubated on ice for 2 h. The beads were washed five
times in the incubation buffer (increased to contain 0.3% NP-40). The last wash
was removed, and adherent labeled E2 protein was analyzed by gel electrophore-
sis and autoradiography.
RESULTS
Identification of PKR autophosphorylation sites. To identify
the sites that are autophosphorylated when PKR is activated in
vitro, we labeled PKR with [g-32P]ATP in the presence of
reovirus dsRNA and then fragmented the protein with cyano-
gen bromide as described previously (51). The predicted pat-
tern of PKR cleavage at methionine residues with cyanogen
bromide is depicted in Fig. 1A. Nine peptides ranging from 1.0
to 11.6 kDa are expected if cleavage is complete. The products
were separated by HPLC. Fractions were collected, counted by
Cerenkov radiation, and pooled as shown in Fig. 1B. Four
major peaks, peaks A to D, were obtained. Analysis of radio-
active peaks A and B was reported previously (51). When pool
C, acquired from the most prominent peak, was resolved in a
Tris-Tricine gel, phosphorylated peptides migrating with ap-
parent molecular masses of 10.3 and 15.5 kDa were observed
together with a minor peptide at ;21 kDa (Fig. 1C, lane 2).
Two of these peptides (15.5 and 21 kDa) probably represent
partial digestion products, as the largest peptide predicted
after cyanogen bromide digestion is 11.6 kDa (Fig. 1A) and
secondary digestion of the 15.5-kDa peptide with cyanogen
bromide yielded only a 10.3-kDa radioactive peptide (data not
shown).
Phosphoamino acid analysis demonstrated that both phos-
phoserine and phosphothreonine were present in the 15.5- and
10.3-kDa bands (51). Pool D contained similar peptides, al-
though the 10.3-kDa peptide was relatively less abundant (51),
and pools C and D gave identical results upon subsequent
analysis. A 10.3-kDa peptide was also released by cyanogen
bromide treatment of phosphorylated p20, a subfragment of
FIG. 1. CNBr digestion of PKR. (A) Sites of cleavage resulting
from CNBr digestion of PKR are predicted, based on the specificity of
CNBr, to cleave peptide bonds at the C-terminal side of methionine
residues. (B) Radiolabeled phosphopeptides derived by CNBr cleav-
age of PKR were separated by reverse-phase HPLC. Fractions were
collected and assayed for radioactivity. (C) Radiolabeled peptides re-
sulting from CNBr cleavage of PKR were resolved in Tris-Tricine gels.
Lane 1, digest of 32P-PKR; lane 2: pool C. (D) Radioactive sequencing
was performed after secondary digestion with the proteases listed.
Radioactive peaks were obtained at the cycle numbers shown. The
cycle numbers containing the largest amounts of radioactivity are un-
derlined and in boldface. (E) Interpretation of the sequencing results.
The amino acid sequence of a PKR peptide (residues 69 to 90) is
shown. Arrows, protease recognition sites within the peptide for pro-
teases Lys-C, trypsin, chymotrypsin, and V8. Numbers were obtained
from analysis of Edman degradation reactions shown in panel D. p,
autophosphorylated amino acids.
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PKR containing residues 1 to 184 (data not shown). As re-
ported previously, recombinant p20 can be phosphorylated by
PKR (48). This finding suggested that the 10.3-kDa peptide
comes from the dsRNA-binding domain of PKR.
No peaks of radioactivity were released upon the direct
sequencing of the material in pools C or D. Radioactivity did
remain bound to the filter, however, indicating that the N
terminus of this peptide was blocked or that the phosphoamino
acids were located past the point of efficient sequencing (;25
to 30 amino acids). To test the latter possibility, material in the
two pools was subjected to secondary digestion with one or two
of six specific proteases. The positions of labeled amino acids
were identified by counting the radioactivity of the products of
sequential Edman degradation reactions. Radioactive peaks
were obtained, and the results are tabulated in Fig. 1D. A
summary of the sequencing data is shown in Fig. 1E. Compar-
ison with the PKR sequence indicated that serine 83 and one
or more of threonines 88, 89, and 90 were phosphorylated.
Several factors make it difficult to discriminate unambigu-
ously among the three threonine residues, most notably the
occurrence of multiple neighboring cleavage sites and the pro-
pensity of the proteases for partial cleavage. Two of the pro-
teases used for secondary digestion recognize lysine (trypsin,
Lys-C) or leucine (chymotrypsin), and incomplete digestion
products were obtained because of the presence of two lysines
and three leucines just upstream of the phosphorylation site
(Fig. 1E). These proteases cleave at the C-terminal side of
amino acids in a peptide, and in a run of identical residues they
tend to cleave preferentially between the residues rather than
after them. Thus the C-terminal residue in the run may not be
recognized by the protease, leaving that amino acid on the N
terminus and causing a shift or “stuttering” in the profiles of
radioactivity obtained after Edman degradation reactions.
Nevertheless, detailed examination of the profiles suggested
that threonines 88, 89, and 90 are all phosphorylated. In ra-
dioactive sequencing experiments of this kind, a declining trail
of radioactivity is generally observed in the Edman degrada-
tion cycles that follow the position of the radiolabeled amino
acid. The pattern of increased yield followed by some carryover
or “lag” derivatives (due to incomplete release of the phos-
phoamino acid derivative from the filter) is often used as a
criterion to assess whether the yield of the phosphoamino acid
is significantly greater than background. In the sequencing
reactions of pools C and D with chymotrypsin, V8, and Lys-C
(Fig. 1D), however, the radioactive peaks corresponding to the
first threonine position were followed by two higher peaks,
corresponding to the second and third threonine, and then a
trail of radioactivity, indicating that all three threonines are
phosphorylated. Thus we conclude that four residues, serine 83
and threonines 88, 89, and 90, located in the spacer between
the two dsRBMs, are probably all phosphorylated.
Phosphorylation of PKR peptides in vitro. To corroborate
the sequencing data, we tested two synthetic peptides corre-
sponding to the RBD spacer region (P1; amino acids 77 to 113)
and the central region of PKR surrounding serine 242 (P2;
amino acids 230 to 254). Both P1 and P2 were phosphorylated
efficiently by PKR (Fig. 2A and B), verifying that they are
substrates for phosphorylation by PKR and that these sites can
be recognized by intermolecular phosphorylation. Phospho-
amino acid analysis (Fig. 2C) revealed that P1 is labeled on
both the serine and the threonine residues whereas P2 is la-
beled on serine only, as expected. The phosphorylation of P1
and P2 continued after PKR autophosphorylation reached
saturation (Fig. 2B); under these conditions, neither of the
peptides interfered with PKR autophosphorylation (data not
shown), suggesting that they do not compete effectively with
the activation reaction.
Autophosphorylation sites in the RNA-binding domain do
not affect PKR function in yeast. To examine the significance
of the four autophosphorylation sites in the RBD spacer, the
serine and three threonine residues were all changed to ala-
nine (Fig. 3A). This PKR RBD mutant (S83A/T88A/T89A/
T90A) was tested in yeast together with wild-type PKR and
three other mutants: K296R, which is inactive as a result of a
mutation in the ATP-binding/phosphotransfer site (23); Triple
mutant S242A/T255A/T258A, which is partially inactivated by
three mutations in the central region (51); and Tri-RBD, which
FIG. 2. Phosphorylation of peptides by PKR. (A) Kinetics of pep-
tide phosphorylation. Reactions were stopped at different time points
(a, 0 min; b, 4 min; c, 8 min; d, 16 min; e, 28 min; f, 44 min; g, 66 min;
h, 108 min; I, 133 min; j, 190 min). (B) Quantitation of PKR auto-
phosphorylation and peptide phosphorylation. Data from panel A are
presented as percentages of maximal 32P labeling. h, P1 phosphory-
lation; n , PKR phosphorylation in the presence of P1; , P2 phos-
phorylation; , PKR phosphorylation in the presence of P2. (C) Phos-
phorylated peptides were subjected to phosphoamino acid analysis by
hydrolysis, two-dimensional separation, and autoradiography. Posi-
tions of markers, detected by ninhydrin staining, are circled.
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contains all seven of the mutations in the Triple and RBD
mutants.
Transformants of yeast strain H1816, which carries a wild-
type eIF2a allele, were grown on selective media to analyze
mutant kinases for their activity (13). Yeast cells that express
fully active PKR cannot grow on galactose medium (SGAL)
due to overexpression of PKR (driven by the Gal promoter)
and consequent phosphorylation of eIF2a. In contrast, expres-
sion of PKR at much lower levels on dextrose-containing me-
dium allows cells to grow in the presence of 3-aminotriazole
(SD13AT), an inhibitor of histidine biosynthesis, because a
moderate level of eIF2 phosphorylation allows for GCN4
translation (Fig. 3B). Cells transformed with inactive PKR
mutants, such as K296R, grow on both synthetic minimal dex-
trose (SD) and SGAL media but not on SD13AT (Fig. 3B).
The phenotype of yeast cells transformed with the RBD mu-
tant was indistinguishable from that of cells transformed with
wild-type PKR, suggesting that the RBD mutant is fully active.
Furthermore, the slow-growth phenotype conferred by the Tri-
ple mutant in SD13AT medium (51) was not exacerbated in
the Tri-RBD mutant (Fig. 3B). This slow-growth phenotype is
attributable to mutations in the central region, most notably
T258A, which is important to the activation of PKR (51).
These data indicate that phosphorylation of residues in the
RBD spacer is not required for PKR function in yeast cells.
Phosphorylation state of PKR in vivo. To determine specif-
ically whether these residues are required for autophosphory-
lation of PKR in vivo, yeast strain H1817 was transformed with
wild-type or mutant forms of PKR. This strain contains the
S51A mutation of eIF2a, allowing for high expression of both
active and inactive PKR (13). The yeast was grown under
inducing conditions (43), and extracts were treated with lamb-
da phosphatase or were incubated with phosphatase buffer
alone. These extracts were then resolved in an SDS gel, trans-
ferred to nitrocellulose, and probed with monoclonal anti-PKR
antibody.
Wild-type PKR showed a distinct increase in gel mobility
upon phosphatase treatment (Fig. 4A), as observed previously
(42). Catalytically inactive mutant K296R migrated with the
phosphatase-treated form and showed no shift in mobility
upon phosphatase treatment, indicating that yeast does not
contain endogenous kinases that phosphorylate PKR. When
the Tri-RBD mutant, carrying seven alanine substitutions, was
treated with phosphatase, it showed a small but reproducible
shift in mobility (Fig. 4A), indicating that the mutant kinase is
phosphorylated to some extent in vivo. This conclusion was
confirmed by labeling with 32P in vivo and analysis of peptides
derived by cyanogen bromide cleavage. Consistent with the
removal of the seven sites of phosphorylation in the RBD and
central region, phosphopeptides of 3.5, 10.3, and 15.5 kDa
were missing. The digest did, however, yield the 21-kDa pep-
tide and a peptide migrating faster than 10 kDa (data not
shown), presumably attributable to sites in the activation loop
of the kinase domain (42) or to other potential phosphoryla-
tion sites reported previously (58).
PKR kinase activity in vitro. Although these assays sug-
gested that the RBD mutation did not affect kinase activity or
autophosphorylation in yeast, we wanted to measure the activ-
ities of the mutant kinases directly. PKR was isolated by im-
munoprecipitation from extracts of H1817 strains carrying mu-
tant or wild-type forms of the enzyme. The amount of PKR
protein recovered was normalized by immunoblotting (as
shown in Fig. 4A), and its activity was assessed in kinase assays.
Figure 4B shows that wild-type PKR was active for autophos-
phorylation and for phosphorylation of eIF2a, while K296R
was inactive in both respects. The Triple mutant was weakly
active, and S242A was highly active, as expected from pub-
lished results (51). Consistent with the in vivo data, the RBD
mutations alone did not affect PKR autophosphorylation or
the phosphorylation of eIF2a and modestly exacerbated the
FIG. 3. PKR mutations and yeast growth. (A) Schematic of PKR
autophosphorylation site mutations. Serine and threonine residues
were changed to alanine to generate Triple and RBD mutants and the
combination mutant; Tri-RBD, which has all seven sites changed to
alanine. (B) Results of yeast growth assays. Transformed cells (H1816)
were grown on SD medium and were replica plated to SGAL and
SD13AT medium for growth analysis (43). 1, strong growth; 6, slow
growth; 2, no growth.
FIG. 4. Properties of PKR mutants. (A) PKR phosphorylation
state. Total cellular protein extracts from transformed H1817 cells
were treated with lambda phosphatase (1) or phosphatase buffer
alone (2), resolved in SDS–10% polyacrylamide gels, and analyzed by
Western blotting with a monoclonal anti-PKR antibody (30) and
chemiluminescence detection. wt, wild type. (B) Kinase activity. Au-
tophosphorylation of wild-type and mutant PKR and phosphorylation
of eIF2a were conducted in vitro. Kinase assay mixtures contained
PKR, isolated on antibody-coated beads, in the presence (1) or ab-
sence (2) of eIF2. Detection was by gel electrophoresis and autora-
diography.
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effects of the Triple mutation when the mutations were present
together in Tri-RBD (Fig. 4B). Thus, the RBD sites influence
kinase activity modestly in vitro.
In view of their location, we also considered the possibility
that the RBD phosphorylation sites might play a role in RNA
binding. To address this possibility, we measured the ability of
immobilized PKR, isolated by immunoprecipitation from yeast
as described above, to interact with 32P-labeled synthetic
dsRNA. Mutations in the RBD did not significantly alter the
retention of dsRNA by PKR (data not shown).
Expression of PKR mutants in mammalian cells. To exam-
ine the effect of the RBD mutations in mammalian cells, we
measured the levels of mutant PKR during transient expres-
sion assays (Fig. 5). Cytoplasmic extracts were prepared from
transfected COS1 cells, and equal amounts of total proteins
were resolved in a gel; PKR expression was monitored by
Western blotting. Plates were transfected in duplicate, and the
immunoblot was probed with antibodies against human PKR
(top) and actin (bottom). As observed previously (42, 54) PKR
mutant K296R was expressed at a much higher level than
wild-type PKR, indicating that this mutant is unable to down-
regulate its expression because it is inactive. Both the Triple
and RBD mutants were expressed at very low levels, indicating
that these mutants are active. The Tri-RBD mutant, however,
was expressed at an intermediate level, lower than that for
K296R but higher than those for the other mutants, indicating
that this mutant is less active than either the Triple or RBD
mutant but not as inactive as K296R. Thus, the RBD sites
contribute to, but are not essential for, the activity of the
kinase.
Peptide competition and HCV E2 inhibition. We previously
showed that HCV E2 binds to PKR and inhibits its kinase
activity, as measured by its ability both to become autophos-
phorylated and to phosphorylate a histone H2a substrate (52).
To determine whether HCV E2 can inhibit phosphorylation of
peptides corresponding to its autophosphorylation sites, acti-
vated PKR was incubated with E2 in a kinase assay containing
P1 or P2. Figure 6A shows that GST-E2 efficiently blocked the
phosphorylation of peptide P1 (lane 6). The phosphorylation
of P2 was also inhibited but to a lesser extent (lane 7), but GST
protein did not significantly inhibit P1 or P2 phosphorylation
(lanes 3 and 4). As discussed previously (52), GST-E2 did not
affect PKR autophosphorylation in this system due to its pre-
activation state.
Deletion of or mutations in the PePHD in HCV E2 abrogate
its functional interaction with PKR (52). We therefore tested
the ability of the two PKR peptides to interfere with the bind-
ing of E2 to PKR. As shown in Fig. 6B, the interaction between
PKR and HCV E2 was not blocked by either peptide P1 or P2.
Concentrations of P1 as high as 60 mg/ml failed to prevent the
binding of E2 to PKR. Thus E2 is a strong ligand for PKR and
can compete with substrates that are trans-autophosphoryla-
tion sites, but it is not displaced from PKR by high concentra-
tions of peptide substrates corresponding to these sites.
DISCUSSION
PKR is found in most mammalian cells at a low level, and
expression of the enzyme is induced by interferon. The kinase
is activated by viral infection in cells and by binding to dsRNA
in vitro (33). Autophosphorylation on several serine and thre-
onine residues, which accompanies activation (18, 29), is be-
lieved to be instrumental in converting the enzyme to a state in
which it is able to phosphorylate its substrates including eIF2.
Previously we identified three autophosphorylation sites in the
central region of PKR and one or two sites in the kinase
FIG. 5. Expression of PKR mutants in mammalian cells. COS1
cells were transfected in duplicate with plasmids encoding wild-type
(WT) or mutant PKR together with pEGFP-C1 (Clontech) encoding
green fluorescent protein. Transfection efficiency was monitored by
observing the ratio of green fluorescent cells to the total number of
cells. Protein expression was monitored by immunoblotting with a
PKR monoclonal antibody (30) and an antiactin antibody.
FIG. 6. HCV E2 competition with PKR autophosphorylation site peptides. (A) Kinase assay mixtures contained PKR immunoprecipitated
from yeast extracts. PKR was incubated with GST or GST-E2 proteins and peptide P1 or P2 before adding [32P]ATP. Incorporation of 32P into
PKR and peptides was monitored by gel electrophoresis and autoradiography. (B) E2 binding assays. Nickel nitrilotriacetic acid-agarose-bound
histidine-tagged PKR was incubated with peptide P1 (1, 5, 15, and 60 mg/ml [lanes 2 to 5]) or peptide P2 (0.6 and 2.4 mg/ml [lanes 6 and 7]) or
without added peptide (lane 1) and then with 35S-labeled E2 protein. Binding was monitored by gel electrophoresis and autoradiography.
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domain that participate in the activation of the enzyme (42,
51). These sites did not appear to be the most prominent
autophosphorylation sites in vitro, however (51). Data pre-
sented here identify amino acids in the spacer region of the
RBD, serine 83 and threonines 88, 89, and 90, as major sites of
phosphorylation in vitro. Mass spectrometry analysis of PKR
isolated from yeast demonstrated that phosphorylation of the
same sites also occurs in vivo (58).
The mutagenic analysis reported here suggests that the au-
tophosphorylation sites in the RBD are involved in, but are not
required for, kinase activation. This inference is supported by
the observation (31) that large deletions in the RBD did not
affect activation of the kinase when endogenous PKR was
present. In these experiments the activation of mutant PKR
that could not become activated through dsRNA binding (in
the absence of the RBD) was presumably brought about either
through trans-phosphorylation by endogenous PKR or by re-
moval of an autoinhibitory domain located in the RBD. Evi-
dence in support of the latter mechanism comes from the
finding that deletions within the RBD can lead to elevated
kinase activity in vitro (57, 59). These data imply the existence
of a negative regulatory element in the RBD; by extension,
dsRNA binding may serve as a trigger to relieve the inhibition
(41).
In combination with sites in the central region of PKR, the
RBD autophosphorylation sites appear to play a role in acti-
vation of the kinase in vitro and in mammalian cells. They do
not affect kinase activity to a detectable extent in the yeast
growth assay, however, where subtle changes in kinase activity
or RNA-binding affinity may be missed because of the abun-
dance of dsRNA molecules in yeast. It is possible that the small
decrease in activity reflects a change in dsRNA binding or
release due to the additional negative charge provided by the
addition of phosphate groups to the RBD sites. Efficient acti-
vation of PKR by dsRNA requires two dsRBMs and is ad-
versely affected by a large deletion in the spacer between them,
although a small deletion was tolerated (21). A recent struc-
tural study of the RBD by nuclear magnetic resonance tech-
niques indicates that the spacer constitutes a flexible linker
between the dsRBMs, allowing the RBD to wrap around the
dsRNA (35). Thus it is conceivable that phosphorylation in the
spacer limits this flexibility. Such constraints might have several
consequences for the specificity of RNA binding. First, the
constraints could restrict the size range of dsRNA molecules
that can interact with PKR; second, in view of the growing
body of evidence that PKR can be activated or blocked by
molecules that are not fully duplexed (3, 9), the constraints
might impose restrictions on the spectrum of partially du-
plexed RNAs that serve these functions; third, they might aid
in discriminating between activators and inhibitors. Further-
more, it is possible that PKR may need to dissociate from
structures with which it interacts in vivo to trans-phosphorylate
substrates or other PKR molecules. Since RBD phosphoryla-
tion does not reduce PKR’s RNA-binding affinity significantly,
there is no evidence that it participates in the release of PKR
from dsRNA, but phosphorylation of PKR may influence its
functional interaction with ribosomes or its distribution or
transport between subcellular compartments.
We note that PKR is activated by autophosphorylation of
the third basic domain and the activation loop in the kinase
domain (42, 51). Our finding that PKR can trans-phosphory-
late peptides that contain PKR autophosphorylation sites, even
after PKR autophosphorylation has reached saturation, indi-
cates that these sites (serine 242, serine 83, and threonines 88,
89, and 90) can be phosphorylated through an intermolecular
mechanism.
Together with the four to five sites identified previously (42,
51) the present work brings the total of PKR autophosphory-
lation sites identified to date to nine. Within this set, threo-
nines outnumber serines by seven to two. Previous reports have
demonstrated that PKR yields considerably more phospho-
serine than phosphothreonine (29), so it seems likely that ad-
ditional sites remain to be characterized. The sequences sur-
rounding the known autophosphorylation sites are listed and
aligned in Table 1. Among the PKR substrates, phosphoryla-
tion sites have been identified for the a subunit of eIF2 (39),
for Tat (5), and for p53 (11); these sites are also included in
Table 1.
Little homology is readily apparent among the sites, but,
strikingly, eight amino acids in the phosphorylated region of
the RBD are identical to residues in the HCV envelope pro-
tein, E2 (Table 2). Moreover, the homology extends upstream.
These observations led to the discovery that the E2 protein
from IFN-resistant strains of HCV is an inhibitor of and po-
tential substrate for PKR (52). Previously it was shown that
HCV E2 inhibits PKR autophosphorylation and substrate
phosphorylation in vitro (52). Here we show that HCV E2
binds efficiently to PKR and that this interaction cannot be
dissociated by a peptide (P1) that contains the homologous
PKR sequence, even though P1 contains autophosphorylation
sites and is a trans-phosphorylation substrate. Nevertheless,
phosphorylation of this peptide is efficiently inhibited by E2,
TABLE 1. PKR phosphorylation sitesa
Protein and amino acid Sequence
eIF2a............................................................... L S E L S R R R I
Tat ................................................................... G Q S S T H Q V S
p53................................................................... E G P D S D
PKR
Ser 242 ........................................................ K A K R S L A P R
Thr 255 ....................................................... D M K E T K Y T V
Thr 258 ....................................................... E T K Y T V D K R
Ser 83 .......................................................... K K A V S P L L L
Thr 88, 89, 90............................................. P L L L T T T N S
Thr 446 ....................................................... D G K R T R S K G
Thr 451 ....................................................... R S K G T L R Y M
a Sequences surrounding known PKR phosphorylation sites within PKR itself
and in its substrates eIF2a, human immunodeficiency virus type 1 Tat, and p53
are aligned. Phosphorylated amino acids are in boldface. Uncharged (L and V)
and basic (K or R) amino acids within 1 to 3 residues of phosphorylation sites are
underlined.
TABLE 2. HCV E2 sequence alignmenta
Protein Sequence
PKR.......................E I L N K E K K A V S P L L L T T T
p p p p p p p ! ! ! ! ! ! ! !
E2 ..........................D L E D R D R S E L S P L L L T T T
a Alignment between amino acids 73 to 90 of PKR, including the RBD phos-
phorylation sites (underlined) and amino acids 270 to 287 of the HCV E2
protein. p, conserved amino acids; !, identical amino acids.
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indicating that E2 is a potent inhibitor of PKR autophosphor-
ylation as well as substrate phosphorylation and that this action
is not carried out through a simple competitive mechanism.
These data imply that mimicry of the autophosphorylation site
by HCV E2 contributes to its inhibition of PKR via a pseu-
dosubstrate mechanism. In addition, other regions of the E2
protein may also be involved, possibly acting to stabilize the
PKR-E2 interaction by reducing the “off” rate. Thus, duplica-
tion of a major PKR autophosphorylation site is part of the
strategy evolved by HCV for evading the effects of IFN, but
further work is required to fully uncover this aspect of the E2
protein’s function.
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